Metabolic disease is among the few health challenges that now reach every region of the world.
The International Diabetes Federation (IDF) estimates that around one in nine adults is living with diabetes, and obesity has risen steadily alongside it, in high-income and low-income countries alike, placing growing pressure on health systems, families and individuals.¹
Southeast Asia is very much part of this picture, with the number of overweight and obese adults continuing to climb across much of the region. Regional analysis has found that the prevalence of overweight and obese adults in Southeast Asia rose by almost 40% between 1990 and 2013.2 More recent data from Malaysia show that 54.4% of adults were overweight or obese in 2023, a 22% increase since 2011.³
As these are long-term conditions that shape quality of life as much as lifespan, attention is turning to ingredients that can support metabolic balance as part of everyday routines. Botanicals with long traditions of use, including those rooted in Ayurveda, are an important area of interest.
The rise of berberine and its absorption challenge
One such ingredient is berberine, which has attracted growing attention from researchers, supplement manufacturers and consumers in metabolic health. Derived from plants including Berberis aristata, a botanical with a long history of use in Ayurveda, this bioactive alkaloid is being investigated for its potential roles in glucose and lipid regulation, weight management and inflammation.4
As consumer interest in metabolic wellness continues to expand, berberine offers formulators an opportunity to build on traditional botanical knowledge while responding to increasingly science-conscious consumers. However, familiarity with an ingredient does not necessarily translate into consistent performance in a finished supplement.
One of the principal challenges associated with conventional berberine is its poor aqueous solubility, alongside limitations in bioaccessibility and pharmacokinetic performance. In practical terms, the amount of an ingredient consumed does not necessarily reflect the amount that becomes available for absorption or reaches systemic circulation. These limitations have prompted researchers and ingredient developers to investigate ways of improving berberine absorption and exposure.
For formulators, the question is therefore not simply whether berberine has potential, but how its delivery can be improved and its performance better understood. This is the challenge that Greenspace Herbs set out to address with BerberineQA, which is a standardised Berberis aristata extract manufactured in India and developed using the company’s proprietary Energized Active Supplement Ingredient (EASI) technology to create enhanced bioavailability berberine.
Wider research approach to berberine
BerberineQA starts with a standardised Berberis aristata extract, which is then processed using EASI technology. This is a proprietary processing platform that is designed to apply quantum chemistry principles to optimise the biopharmaceutical properties of botanical extracts, improving aqueous solubility and systemic bioavailability without chemical modification.
The company’s approach is based on the premise that understanding botanical ingredients requires more than identifying their active compounds. Greenspace’s wider research approach explores electronic configurations and resonance energy levels, using these data to inform its development of herbal ingredients and formulations.
Quantum Ayurveda combines its interpretation of traditional Ayurvedic knowledge with concepts from quantum chemistry. The aim is to use a deeper understanding of ingredient properties to inform product development, while evaluating the resulting products through conventional scientific methods.
Artificial intelligence also forms part of Greenspace’s wider research platform, as the technology is used to analyse extensive datasets relating to botanical compounds, pharmacology and biochemistry, helping researchers investigate potential mechanisms of action and identify promising formulation approaches.
The latest pharmacokinetic findings
A human pharmacokinetic study by Greenspace, led by its R&D team, compared BerberineQA with standard berberine hydrochloride in an open-label crossover design.5 Twenty-four healthy adult men completed both study periods, receiving a single 500 mg dose of each ingredient under fasting conditions. Plasma concentrations were measured over 24 hours using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
According to the study results, total systemic exposure, measured through the area under the plasma concentration-time curve over 24 hours, was approximately 12.8 ng·h/mL for BerberineQA, compared with 3.4 ng·h/mL for standard berberine hydrochloride. This corresponds to approximately fourfold higher exposure over the measurement period.
The time taken to reach maximum plasma concentration (Tmax) was shorter for BerberineQA, at approximately 2.5 hours, compared with around four hours for standard berberine hydrochloride. The reported elimination half-life was approximately eight hours, against 4.5 hours for the comparator.
Peak plasma concentration (Cmax) was reported at approximately 1.2 ng/mL for BerberineQA, compared with around 0.07 ng/mL for standard berberine hydrochloride, an approximately 18-fold difference.
Taken together, these results suggest that the ingredient produced greater measured systemic exposure, an earlier peak, a longer half-life, and higher peak concentrations than standard berberine following the same dose. No serious adverse events were reported, and the treatments were well tolerated.
For R&D and new product development teams, these findings offer a starting point for examining how differences in ingredient delivery could inform formulation strategies to incorporate clinically-studied berberine.
From botanical tradition to evidence-led innovation
The pharmacokinetic data describe how BerberineQA behaves in the body. For ingredient developers, the other half of the assessment is the ingredient itself. BerberineQA is a standardised Berberis aristata extract with a minimum of 97% berberine, verified by HPLC, manufactured in Karnataka, India, at a facility certified for HACCP and FSMS. Its specification sets limits for heavy metals by ICP-MS, microbial counts and pesticide residues in line with USP <565>.
Consistency over time is the next consideration. In company testing of a single batch, berberine content measured 97.52% after six months under real-time conditions (25°C/60% relative humidity) and 97.46% under accelerated conditions (40°C/75% relative humidity), both above the specification of not less than 97%, with moisture and microbial limits met throughout.
The ingredient carries a shelf life of 36 months in its original, unopened packaging, and is supplied in labelled aluminium bags packed in HDPE containers, with air freight handled in line with IATA/ICAO regulations. The premium berberine ingredient is suited to formulation into stick packs, capsules, and gummies.
With absorption data published and quality documentation in place, the natural next question for berberine research is how the measured differences in exposure relate to efficacy, dosing and long-term use. Greenspace works with partners across Southeast Asia to assess how high-absorption berberine fits the requirements of their formulations, supported by the published data and technical documentation.
References
- International Diabetes Federation. Diabetes facts and figures [Internet]. Brussels: International Diabetes Federation.
- Helble, M.; et al. The Imminent Obesity Crisis in Asia and the Pacific: First Cost Estimates. ADBI Working Paper No. 743. Tokyo: Asian Development Bank Institute; 2017.
- Mat Rifin, H.; et al. Conducting the National Health and Morbidity Survey 2023 in Malaysia with focus on methodology and main findings on non-communicable diseases. Sci Rep. 2025;15(1):25531.
- Shi, L.; et al. Berberine and health outcomes: an overview of systematic reviews. BMC Complement Med Ther. 2025;25(1):147.
- Tahira, HS.; et al. Pharmacokinetic Study of BerberineQA™ Versus Standard Berberine Extract in Healthy Humans: An Open Label, Randomized Single-Dose, Crossover Study. J Ayu Int Med Sci. 2026;11(4):71-76.
